What question did this study set out to answer?

The research aims to investigate the effects of ticagrelor on renal cell carcinoma growth through a specific signaling pathway.

March 1, 2026Open Access

Drug repurposing of ticagrelor suppresses renal cell carcinoma growth by blockading the EGFR/PI3K/AKT axis.

Resultado clave

Ticagrelor suppresses renal cell carcinoma growth by blocking the EGFR/PI3K/AKT signaling pathway, indicating its potential as a therapeutic agent.

Puntos clave

The research aims to investigate the effects of ticagrelor on renal cell carcinoma growth through a specific signaling pathway.
Experimental intervention with ticagrelor
Analysis of RCC cell growth and signaling pathways
Assessment of EGFR, PI3K, and AKT activation levels
Ticagrelor significantly reduces RCC cell growth
Inhibition of the EGFR/PI3K/AKT signaling pathway observed
Potential for ticagrelor as a therapeutic target and biomarker in RCC

PICO estructurado

Does ticagrelor suppress renal cell carcinoma growth?

Población

Renal cell carcinoma (RCC)

Intervención

Ticagrelor

Resultado

Renal cell carcinoma growth suppressionsurrogate

Ticagrelor demonstrates potential for drug repurposing in renal cell carcinoma by suppressing growth via the EGFR/PI3K/AKT axis.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Ticagrelor exerts anti-RCC effects via blockade of the EGFR/PI3K/AKT signaling axis, highlighting its translational potential and positioning this pathway as a therapeutic target and possible biomarker in RCC.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo